David Henry Mack - 01 Jul 2025 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
President and CEO, Director
Signature
/s/ Robert Ticktin, by power of attorney
Issuer symbol
PMVP
Transactions as of
01 Jul 2025
Net transactions value
-$62,179
Form type
4
Filing time
03 Jul 2025, 19:48:00 UTC
Previous filing
05 Mar 2025
Next filing
29 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mack David Henry President and CEO, Director C/O PMV PHARMACEUTICALS, INC., 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON /s/ Robert Ticktin, by power of attorney 03 Jul 2025 0001341642

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Sale $62,179 -58,411 -9.8% $1.06 536,133 01 Jul 2025 Direct F1, F2
holding PMVP Common Stock 165,307 01 Jul 2025 See footnote F3
holding PMVP Common Stock 147,915 01 Jul 2025 See footnote F4
holding PMVP Common Stock 56,978 01 Jul 2025 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units, or RSUs.
F2 Includes 15,528 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2025.
F3 The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F4 The shares are held of record by the Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F5 The shares are held of record by the Mack/Mulligan 2020 Irrevocable Descendants' Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.